Home » Topics » Nephrology, BioWorld Science

Nephrology, BioWorld Science
RSS

Clinical trial program for RenaGel continues on schedule

Nov. 8, 1996

Synaptic, Merck extend BPH collaboration

Nov. 8, 1996

CV Therapeutics reports novel adenosine antagonist

Nov. 8, 1996

Potential use of phytopharmaceutical compounds for BPH

Nov. 1, 1996

Muscarinic antagonists from Yamanouchi

Oct. 25, 1996

New alternative available for BPH

Oct. 18, 1996

Merck persists in the search for BPH therapeutics

Oct. 18, 1996

Renal-urologic drugs in development at Yamanouchi

Oct. 11, 1996

Three renal-urologic drugs reported in the Fujisawa product pipeline

Oct. 11, 1996

New BPH therapy cleared by the FDA

Oct. 11, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
In the clinic for April 21, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Abbott, Agenus, Astrazeneca, Briacell, Clearmind, Greenwich, Intodna,...